Full Text:   <2727>

CLC number: R58

On-line Access: 2024-08-27

Received: 2023-10-17

Revision Accepted: 2024-05-08

Crosschecked: 0000-00-00

Cited: 0

Clicked: 5038

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE B 2006 Vol.7 No.9 P.763-765

http://doi.org/10.1631/jzus.2006.B0763


Basal or bolus dose, which is the key factor in CSII?


Author(s):  YANG Nai-long, XUE Bing, LIN Peng

Affiliation(s):  Department of Endocrinology, the Affiliated Hospital of Medical College, Qingdao University, Qingdao 266003, China; more

Corresponding email(s):   nailongy@163.com

Key Words:  Type 2 diabetes mellitus, HbA1c, Basal total daily dose of insulin, CSII (continuous subcutaneous insulin infusion)


YANG Nai-long, XUE Bing, LIN Peng. Basal or bolus dose, which is the key factor in CSII?[J]. Journal of Zhejiang University Science B, 2006, 7(9): 763-765.

@article{title="Basal or bolus dose, which is the key factor in CSII?",
author="YANG Nai-long, XUE Bing, LIN Peng",
journal="Journal of Zhejiang University Science B",
volume="7",
number="9",
pages="763-765",
year="2006",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.2006.B0763"
}

%0 Journal Article
%T Basal or bolus dose, which is the key factor in CSII?
%A YANG Nai-long
%A XUE Bing
%A LIN Peng
%J Journal of Zhejiang University SCIENCE B
%V 7
%N 9
%P 763-765
%@ 1673-1581
%D 2006
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.2006.B0763

TY - JOUR
T1 - Basal or bolus dose, which is the key factor in CSII?
A1 - YANG Nai-long
A1 - XUE Bing
A1 - LIN Peng
J0 - Journal of Zhejiang University Science B
VL - 7
IS - 9
SP - 763
EP - 765
%@ 1673-1581
Y1 - 2006
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.2006.B0763


Abstract: 
Objective: To observe the value of hbA1c level evaluating the total daily basal insulin dose by continuous subcutaneous insulin infusion (CSII) in 268 patients with type 2 diabetes mellitus. Methods: 5-point capillary blood glucose was monitored in pre- and post-CSII and the insulin dose which could stabilize blood glucose was defined as the total daily dose of insulin, including basal and bolus total dose. Correlation between hbA1c level and total daily dose of insulin in patients with type 2 diabetes mellitus was analyzed. Correlation between hbA1c level and 5-point capillary blood glucose was also analyzed. Results: Obvious correlation was observed between hbA1c level and the basal total daily dose of insulin if hbA1c was more than 9.3% (r=0.635, P<0.05). The average of 5-point capillary blood glucose was best correlated with hbA1c and fasting blood glucose next best. Conclusion: hbA1c level can forecast basal total daily dose of insulin in CSII.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1] Abbasi, F., Reaven, G.M., 2002. Relationship between fasting and day-long plasma glucose concentrations in diet-treated patients with type 2 diabetes. Metabolism, 51(4):457-459.

[2] Bonora, E., Calcaterra, F., Muggeo, M., 2001. Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care, 24:2023-2029.

[3] Crawford, L.M., Sinha, R.N., Odell, R.M., Comi, R.J., 2000. Efficacy of insulin pump therapy: mealtime delivery is the key factor. Endocr. Pract., 6(3):239-243.

[4] Knee, T.S., Seidensticker, D.F., Walton, J.L., Solberg, L.M., Lasseter, D.H., 2003. A novel use of U-500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: a case series. Endocr. Pract., 9(3):181-186.

[5] Monnier, L., Lapinski, H., Colette, C., 2003. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care, 26(3):881-885.

[6] Zinman, B., 2000. Basal insulin replacement and use of rapid-acting insulin analogues in patients with type 1 diabetes. Endocr. Pract., 6(1):88-92.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE